Avacta Group PLC
Research Avacta Group PLC (AVCT) on Bullrun: market cap GBX 33.74B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAVCT
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 33.74B
- Financial periodFY2025
- RevenueGBP 113.00K
- Revenue growth0.0%
- Net income-GBP 38.61M
- Free cash flow-GBP 26.84M
- Gross margin100.0%
Valuation Snapshot
latest market cap is GBX 33.74B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 113.00K | -GBP 38.61M | -GBP 26.84M | 100.0% | -0.1 | GBP 16.86M | GBP 14.92M | GBP 2.48M |
| FY2024 | GBP 113.00K | -GBP 52.84M | -GBP 23.94M | 100.0% | -0.15 | GBP 12.87M | GBP 22.94M | GBP 9.28M |
| FY2023 | GBP 2.85M | -GBP 33.26M | -GBP 15.08M | 99.5% | -0.12 | GBP 16.63M | GBP 31.52M | GBP 16.90M |
| FY2022 | GBP 9.65M | -GBP 36.63M | -GBP 17.19M | 75.0% | -0.15 | GBP 41.78M | GBP 23.84M | GBP 21.00M |
| FY2021 | GBP 2.94M | -GBP 26.32M | -GBP 21.82M | 68.6% | -0.11 | GBP 26.19M | GBP 1.70M | GBP 41.22M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-30 | GBX 33.74B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Avacta Group PLC
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Avacta Group PLC's market cap?
Avacta Group PLC's market capitalization is GBX 33.74B.
What does Avacta Group PLC do?
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities.